Entity
  • Crystal Pharmatech

    Created in 2010
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    518 4,966
  • Activities

  • Technologies

  • Entity types

  • Location

    3000 Eastpark Blvd #500b, Cranbury, NJ 08512, USA

    South Brunswick Township

    United States of America

  • Employees

    Scale: 201-500

    Estimated: 70

  • Engaged corporates

    4
    0 4
  • Added in Motherbase

    1 year, 1 month ago
Description
  • Value proposition

    A Leading CRO/CDMO for Solid Form & Formulation, Advancing Your PCC to Phase I and Beyond with First-Time-Right Approach

    Established in 2010, Crystal Pharmatech is a specialized CRO/CDMO, excelling in crystal form and formulation services. Our exceptional track record includes supporting 1,000 clients and collaborating on over 2,000 compounds, showcasing our expertise in solid-state research, crystallization, pre-formulation, formulation development, and manufacturing. With a global presence encompassing three strategically located R&D centers in Suzhou (China), New Jersey (USA), and Toronto (Canada), we are powered by a skilled team of around 250 professionals.

    As a leader in both conventional and enabling formulation technologies, including amorphous solid dispersion, we take pride in our cGMP facilities, strictly adhering to the rigorous standards set by the FDA, EMA, and NMPA. Our integrated service encompasses the entire new drug development journey, from developability assessment and solid form screening to pre-formulation, formulation development, and CTM and commercial manufacturing.

    Introducing our pioneering Mol2Med program, designed to expedite small molecule lead compounds or preclinical candidates into Phase I and beyond, with unparalleled efficiency and precision. This 3-step First-Time-Right approach begins at the lead optimization/PCC stage:

    Step 1: Developability Assessment to guide API form selection and formulation design.
    Step 2: Solid form screening/selection and Preformulation.
    Step 3: Formulation development and CTM manufacturing, including packaging, labeling, and shipping to the clinical site.

    This innovative approach guarantees a robust API form and a scalable manufacturing process, culminating in a First-Time-Right formulation for Phase I. Streamlining the transition to future clinical studies upon Phase I success, our First-Time-Right approach sets the foundation for optimized drug development and success beyond.

    salt screening, polymorph screening, cocrystal screening, API characterization, API process optimization, API crystallization, chiral resolution, preformulation, amorphous solid dispersion, formulation characterization, crystallization development and optimization, Formulation, GMP Manufacturing, Formulation Development, and Clinical and Commercial Manufacturing

  • Crystal Pharmatech: Pharmaceutical CDMO & CRO Services Company

    Crystal Pharmatech has been providing world-leading solid state research and formulation CDMO services to global pharmaceutical companies since 2010. We use Molecule-Material-Medicine (MMM) approach to develop the best crystal and formulation for your molecules. Consult today!

  • https://www.crystalpharmatech.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Biotechnology, Biotechnology Research
Vertex Pharmaceuticals
Biotechnology, Biotechnology Research
Other

24 Feb 2014


Amgen
Amgen
Biotechnology, Biotechnology Research
Amgen
Biotechnology, Biotechnology Research
Other

19 Dec 2013


MSD
MSD
Pharmaceutical, Pharmaceutical Manufacturing
MSD
Pharmaceutical, Pharmaceutical Manufacturing
Other

10 Mar 2014


Sanofi
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Other

4 Feb 2014


Similar entities
Loading...
Loading...
Social network dynamics